ESMO 2023 | Utilizing neoadjuvant immunotherapies in patients with ER+, HER2- primary breast cancer

Sherene Loi, MD, PhD, PeterMacCallum Cancer Centre, Victoria, Australia, discusses the utilization of neoadjuvant immunotherapies for patients with estrogen receptor-positive (ER+) and HER2-negative primary breast cancer following results from the Phase III CHECKMATE-7FL (NCT04109066) trial. The trial demonstrated a significant increase in pathological complete response (pCR) rate with the addition of nivolumab to neoadjuvant chemotherapy, particularly for patients who are PD-L1+. The challenge ahead involves integrating neoadjuvant immunotherapy and possibly adjuvant CDK4 inhibitors, particularly for high-risk groups, impacting treatment, side effects, and costs. The key lies in defining the right group for optimal neoadjuvant therapy, a complex issue with implications for patient care and outcomes. The This interview took place at the European Society for Medical Oncology (ESMO) 2023 Congress in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.